Dynamics of HPV vaccination initiation in Flanders (Belgium) 2007-2009: a Cox regression model

Lefevere, Eva; Hens, Niel; De Smet, Frank; Van Damme, Pierre
January 2011
BMC Public Health;2011 Supplement 4, Vol. 11 Issue Suppl 4, p470
Academic Journal
Background: We investigated dynamic patterns and predictors of HPV vaccination initiation in Flanders (Belgium) by girls aged 12 to 18, between 2007 and 2009, the period immediately after the introduction of the HPV vaccines on the Belgian market. During this period the initiative for vaccination was taken by the girl, her family or the general practitioner/pediatrician/gynecologist. Methods: We used a Cox regression model with time constant and time varying predictors to model hazard rates of HPV vaccination initiation. The sample existed of 117,151 female members of the National Alliance of Christian Mutualities, the largest sickness fund in Flanders. Results: The study showed that the hazard of HPV vaccination initiation was higher (1) for older girls, (2) for girls with a more favorable socio-economic background, (3) under more generous reimbursement regimes (with this effect being more pronounced for girls with weak socioeconomic backgrounds), (4) for girls that were informed personally about the reimbursement rules. Conclusions: When the initiative for HPV vaccination lies with the girls, their families or the physicians (no organized setting) the uptake of the vaccines is affected by both individual and organizational factors.


Related Articles

  • NOTICE BOARD.  // Nursing Standard;8/27/2008, Vol. 22 Issue 51, p62 

    The article presents a calendar of events including and human papilloma virus (HPV) vaccine immunization programme organized by the Department of Health starting September, Anglia Ruskin University and the RCN research society will be awarded the Akinsaya award to the most innovative author of...

  • Acute viscerotropic disease following vaccination against yellow fever. Hayes, Edward B. // Transactions of the Royal Society of Tropical Medicine & Hygiene;Oct2007, Vol. 101 Issue 10, p967 

    Summary: Acute viscerotropic disease following yellow fever vaccination (YEL-AVD) is a rare but serious complication of vaccination with 17D yellow fever vaccine. This paper reviews the existing literature regarding YEL-AVD and discusses possible etiologic mechanisms. A greater understanding of...

  • The Risks and Benefits of HPV Vaccination. Haug, Charlotte // JAMA: Journal of the American Medical Association;8/19/2009, Vol. 302 Issue 7, p795 

    The author comments on the risks and beneficial effects of human papillomavirus (HPV) vaccine. She examines the theory behind the vaccine, and argues on the right vaccine that could prevent HPV infection. She discusses the two papers published which present significant data that may influence...

  • HPV vaccine recombinant quadrivalent: safety concerns.  // Reactions Weekly;2/17/2007, Issue 1139, p3 

    The article reports on the call of the U.S. National Vaccine Information Center (NVIC) for state legislatures to investigate the safety and cost of introducing Merck's human papillomavirus vaccine recombinant quadrivalent Gardasil for all pre-adolescent girls prior to introducing changes to...

  • Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02D Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial. Aide, Pedro; Aponte, John J.; Renom, Montse; Nhampossa, Tacilta; Sacarlal, Jahit; Mandomando, Inacio; Bassat, Quique; Manaca, Maria NĂ©lia; Leach, Amanda; Lievens, Marc; Vekemans, Johan; Dubois, Marie-Claude; Loucq, Christian; Ballou, W. Ripley; Cohen, Joe; Alonso, Pedro L. // PLoS ONE;2010, Vol. 5 Issue 11, p1 

    Background: The RTS,S/AS02D vaccine has been shown to have a promising safety profile, to be immunogenic and to confer protection against malaria in children and infants. Methods and Findings: We did a randomized, controlled, phase I/IIb trial of RTS,S/AS02D given at 10, 14 and 18 weeks of age...

  • Pathogenic epitopes, heterologous immunity and vaccine design. Welsh, Raymond M.; Fujinami, Robert S. // Nature Reviews Microbiology;Jul2007, Vol. 5 Issue 7, p555 

    Substantial research has been directed towards the development of a new generation of vaccines that are based on the inclusion of immunogenic epitopes in recombinant vectors. Here we examine the evidence that under certain conditions immunogenic epitopes can do more harm than good and might...

  • New Findings on HPV Transmission. J. O. // School Health Alert;Nov2011, Vol. 27 Issue 3, p4 

    The article presents information on human papillomavirus (HPV), its modes of transmission, vaccines used for treatment of HPV, and other pathological aspects of HPV.

  • HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. Mariani, Luciano; Venuti, Aldo // Journal of Translational Medicine;2010, Vol. 8, p105 

    Although long-term protection is a key-point in evaluating HPV-vaccine over time, there is currently inadequate information on the duration of HPV vaccine-induced immunity and on the mechanisms related to the activation of immune-memory. Longer-term surveillance in a vaccinated population is...

  • Progress Toward Implementation of Human Papillomavirus Vaccination - the Americas, 2006-2010.  // Immunization Newsletter;Oct2011, Vol. 33 Issue 5, p1 

    The article discusses the progress toward human papillomavirus (HPV) vaccine introduction in the U.S. during 2006-2010, focusing on countries that have introduced the vaccine in national or regional immunization programs. It examines issues related to financing and delivery of HPV vaccine, which...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics